| Company Name: | Bio-Rad Laboratories, Incorporated Class A | | Ticker Symbol: | BIO | | | WWW Address: | www.bio-rad.com | | CEO: | Norman Schwartz | | No. of Employees: | 6,600 | | Common Issue Type: | CS | | Business Description: | The Company manufactures & supplies the life science research, healthcare, analytical chemistry & other markets with a range of products & systems used to separate complex chemical & biological materials & to identify, analyze & purify their componen
|
| | | Industry Information: | ELECTRONICS - Scientific & Technical Instruments [more like this] |
|
| Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 99.51 |  1.16 | 93.29 | 105.76 | 98.35 | 99.58 | 98.05 | 87975 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 2,736.5 | 27.5 | 1.07 | 3.25 | 0.00 | 28.0 | 0.0 | 100.99 - 51.33 |
|
| KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 99.51 | $ | | PE Ratio - LTM | 28.0 | |
| Market Capitalisation | 2,224.9 | mil |
| Latest Shares Outstanding | 27.5 | mil |
| Earnings pS (EPS) | 3.25 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 267,328 | $ |
| Effective Tax Rate | 31.2 | % |
| Float | 18.5 | mil |
| Float as % of Shares Outstanding | 67.8 | % |
| Foreign Sales | 1,239 | mil |
| Domestic Sales | 525 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 34.10 | % |
| Research & Devlopment (R&D) as % of Revenue | 9.20 | % |
| Gross Profit Margin | 61.9 | % |
| EBITDA Margin | 18.6 | % |
| Pre-Tax Profit Margin | 8.7 | % |
| Assets Turnover | 0.8 | % |
| Return on Assets (ROA) | 4.1 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | 13.8 | % |
| Current Ratio | 3.6 | |
| Leverage Ratio (Assets/Equity) | 0.0 | |
| Interest Cover | 4.6 | |
| Total Debt/Equity (Gearing Ratio) | 0.00 | |
| LT Debt/Total Capital | 100.0 | % |
| Working Capital pS | 39.58 | $ |
| Cash pS | 20.16 | $ |
| Book-Value pS | 0.00 | $ |
| Tangible Book-Value pS | -19.80 | $ |
| Cash Flow pS | 7.22 | $ |
| Free Cash Flow pS | 5.01 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 0.00 | |
| Price/Tangible Book Ratio | -5.03 | |
| Price/Cash Flow | 13.8 | |
| Price/Free Cash Flow | 19.9 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 21.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | |
| |
| PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 2.0 | 101 | 586 | 1,402 |
| 4 Weeks | 100.99 | 88.25 | 89.39 | 11.3 | 104 | 679 | 11,546 |
| 13 Weeks | 100.99 | 84.50 | 86.50 | 15.0 | 107 | 779 | 47,519 |
| 26 Weeks | 100.99 | 68.90 | 74.44 | 33.7 | 111 | 1,020 | 127,512 |
| 52 Weeks | 100.99 | 51.33 | 74.16 | 34.2 | 109 | 1,102 | 274,503 |
| YTD | 100.99 | 51.33 | - | 32.1 | 108 | 1,072 | 243,380 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 98.55 | 98.81 | 93.88 | 83.46 | 77.88 | 1.07 | 1.15 |
|
| |
| GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | 10.82 | 94.8 | 11.64 |
| Income | 5.15 | 46.2 | -3.04 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 23.60 | NA | 69.58 |
| R&D | 9.46 | NA | 9.88 |
| Normalized Inc. | 6.74 | NA | 3.05 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -2.1 | 4.3 | 20.8 |
| Earnings % | 9.2 | 38.4 | -3.7 |
| EPS % | 8.5 | 36.6 | -4.7 |
| EPS $ | 0.30 | 0.37 | -0.16 |
|
| |
| SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 33.18 |
| Current Ratio | 2.6 |
| Quick Ratio (Acid Test) | 1.4 |
| Liquidity Ratio (Cash) | 0.58 |
| Receivables Turnover | 5.1 |
| Average Collection Period | 71 |
| Working Capital/Equity | 64.9 |
| Working Capital pS | 24.74 |
| Cash-Flow pS | 6.83 |
| Free Cash-Flow pS | 1.81 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 2.98 |
| Financial Leverage Ratio (Assets/Equity) | 2.0 |
| Debt Ratio | 48.9 |
| Total Debt/Equity (Gearing Ratio) | 0.44 |
| LT Debt/Equity | 0.43 |
| LT Debt/Capital Invested | 38.9 |
| LT Debt/Total Liabilities | 44.8 |
| Interest Cover | 5.2 |
| Interest/Capital Invested | 1.98 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 3.47 |
| Tobin's Q Ratio | 1.09 |
| Current P/E Ratio - LTM | 28.00 |
| Enterprise Value (EV)/EBITDA | 9.64 |
| Enterprise Value (EV)/Free Cash Flow | 75.60 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | -5.03 |
| Price/Book Ratio - LTM | 0.00 |
| Price/Cash Flow Ratio | 13.8 |
| Price/Free Cash Flow Ratio - LTM | 19.9 |
| Price/Sales Ratio | 1.57 |
| P/E Ratio (1 month ago) - LTM | 25.8 |
| P/E Ratio (26 weeks ago) - LTM | 22.0 |
| P/E Ratio (52 weeks ago) - LTM | 18.5 |
| 5-Y High P/E Ratio | 33.8 |
| 5-Y Low P/E Ratio | 14.9 |
| 5-Y Average P/E Ratio | 23.7 |
| Current P/E Ratio as % of 5-Y Average P/E | 118 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 21.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 21.8 |
| PER SHARE FIGURES |
| LT Debt pS | 16.32 |
| Current Liabilities pS | 15.30 |
| Tangible Book Value pS - LTM | -19.80 |
| Book Value pS - LTM | 0.00 |
| Capital Invested pS | 54.10 |
| Cash pS - LTM | 20.16 |
| Cash Flow pS - LTM | 7.22 |
| Free Cash Flow pS - LTM | 5.01 |
| Earnings pS (EPS) | 3.25 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | 2.81 |
| Free Cash Flow Margin 5YEAR AVG | -1.46 |
| Net Profit Margin | 5.1 |
| Net Profit Margin - 5YEAR AVRG. | 6.4 |
| Equity Productivity | 1.70 |
| Return on Equity (ROE) | 8.6 |
| Return on Equity (ROE) - 5YEAR AVRG. | 10.7 |
| Capital Invested Productivity | 1.19 |
| Return on Capital Invested (ROCI) | 6.0 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | 7.0 |
| Assets Productivity | 0.90 |
| Return on Assets (ROA) | 4.4 |
| Return on Assets (ROA) - 5YEAR AVRG. | 5.2 |
| Gross Profit Margin | 61.9 |
| Gross Profit Margin - 5YEAR AVRG. | 60.0 |
| EBITDA Margin - LTM | 18.6 |
| EBIT Margin - LTM | 11.0 |
| Pre-Tax Profit Margin | 8.1 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 8.8 |
| Effective Tax Rate | 31.2 |
| Effective Tax Rate - 5YEAR AVRG. | 25.9 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 247 |
| Revenue per Employee | 267,328 |
| Net Income per Employee | 13,562 |
| Average Collection Period | 69 |
| Receivables Turnover | 5.1 |
| Day's Inventory Turnover Ratio | 178 |
| Inventory Turnover | 2.0 |
| Inventory/Sales | 21.3 |
| Accounts Payble/Sales | 8.74 |
| Assets/Revenue | 1.11 |
| Net Working Capital Turnover | 2.61 |
| Fixed Assets Turnover | 1.87 |
| Total Assets Turnover | 0.9 |
| Revenue per $ Cash | 8.63 |
| Revenue per $ Plant | 5.87 |
| Revenue per $ Common Equity | 1.70 |
| Revenue per $ Capital Invested | 1.19 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 33.5 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 34.5 |
| Research & Devlopment (R&D) as % of Revenue | 9.0 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 9.0 |
|
|  
|
| |
 |  |